0 CHECKOUT

Dengue - Pipeline Review, H1 2015

  • ID: 3099755
  • January 2015
  • 187 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Agilvax, Inc.
  • Cocrystal Pharma, Inc.
  • Immunovaccine, Inc.
  • Merck & Co., Inc.
  • PaxVax
  • SKAU Vaccines ApS
  • MORE

Dengue - Pipeline Review, H1 2015

Summary

This, ‘Dengue - Pipeline Review, H1 2015’, provides an overview of the Dengue’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dengue and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Agilvax, Inc.
  • Cocrystal Pharma, Inc.
  • Immunovaccine, Inc.
  • Merck & Co., Inc.
  • PaxVax
  • SKAU Vaccines ApS
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Dengue Overview
Therapeutics Development
Pipeline Products for Dengue - Overview
Pipeline Products for Dengue - Comparative Analysis
Dengue - Therapeutics under Development by Companies
Dengue - Therapeutics under Investigation by Universities/Institutes
Dengue - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Dengue - Products under Development by Companies
Dengue - Products under Investigation by Universities/Institutes
Dengue - Companies Involved in Therapeutics Development
Agilvax, Inc.
AltraVax Inc.
Arbovax, Inc.
BioDiem Ltd
Biotron Limited
Cocrystal Pharma, Inc.
Codagenix, Inc.
FIT Biotech Oyj
GlaxoSmithKline plc
Humabs BioMed SA
Immunovaccine, Inc.
Johnson & Johnson
Kineta, Inc.
MacroGenics, Inc.
Medivir AB
Merck & Co., Inc.
Molplex Ltd.
Myelo Therapeutics GmbH
NanoViricides, Inc.
Panacea Biotec Limited
PaxVax
Prosetta Antiviral Inc.
RFS Pharma, LLC
Sanofi Pasteur SA
Sarepta Therapeutics, Inc.
SIGA Technologies, Inc.
SKAU Vaccines ApS
Takeda Pharmaceutical Company Limited
TechnoVax, Inc.
Themis Bioscience GmbH
United Therapeutics Corporation
VaxInnate Corporation
Visterra, Inc.
Dengue - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BG-323 - Drug Profile
celgosivir hydrochloride - Drug Profile
dengue (tetravalent) vaccine - Drug Profile
dengue (tetravalent) vaccine - Drug Profile
dengue (tetravalent) vaccine 4 - Drug Profile
dengue [DENV-2] vaccine - Drug Profile
dengue [rDEN1delta30, rDEN2/4delta30(ME), rDEN3delta30/31 and rDEN4delta30] (tetravalent) vaccine - Drug Profile
dengue [serotypes 1,2,3,4] (tetravalent) vaccine - Drug Profile
dengue fever vaccine - Drug Profile
dengue vaccine - Drug Profile
dengue vaccine - Drug Profile
dengue vaccine - Drug Profile
dengue vaccine - Drug Profile
dengue vaccine - Drug Profile
dengue vaccine - Drug Profile
dengue vaccine - Drug Profile
dengue vaccine - Drug Profile
dengue vaccine (DENV-2) - Drug Profile
dengue vaccine (tetravalent) - Drug Profile
dengue vaccine (tetravalent) - Drug Profile
dengue vaccine (tetravalent) - Drug Profile
dengue vaccine [DEN-1 and DEN-2] - Drug Profile
dengue vaccine [DEN-2] - Drug Profile
dengue vaccine 3 - Drug Profile
dengue vaccine 4 - Drug Profile
dengue vaccines - Drug Profile
dengue virus vaccine - Drug Profile
dengue virus vaccine (tetravalent) - Drug Profile
DengueCide - Drug Profile
DENV-1 PIV - Drug Profile
DiTU - Drug Profile
DV-2-DeltaGVII - Drug Profile
DV-2-DeltaLIG - Drug Profile
DV-2-G460P - Drug Profile
ETX-101 - Drug Profile
GBV-001 - Drug Profile
GBV-006 - Drug Profile
GBV-012 - Drug Profile
GREDEN/V1-4 - Drug Profile
LCTA-949 - Drug Profile
LVM-142 - Drug Profile
modipafant - Drug Profile
Monoclonal Antibodies for Infectious Disease - Drug Profile
Monoclonal Antibodies to Inhibit prM and E Proteins for Dengue - Drug Profile
Monoclonal Antibody for Dengue - Drug Profile
Monoclonal Antibody for Dengue - Drug Profile
Myelo-001 - Drug Profile
PAV-866 - Drug Profile
Recombinant Peptide to Inhibit Dengue Protease for Dengue - Drug Profile
RNAi Oligonucleotide for Dengue - Drug Profile
rOAS - Drug Profile
RS-1137 - Drug Profile
RS-1142 - Drug Profile
RS-1145 - Drug Profile
RS-930 - Drug Profile
RS-961 - Drug Profile
Small Molecule for Dengue - Drug Profile
Small Molecule for Dengue - Drug Profile
Small Molecule Inhibitors of NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile
Small Molecule to Inhibit NS3 Protease for Dengue - Drug Profile
Small Molecules for Dengue - Drug Profile
Small Molecules for Dengue - Drug Profile
Small Molecules Inhibiting M Protein for Dengue - Drug Profile
Small Molecules to Activate AMPK for Dengue - Drug Profile
Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections - Drug Profile
Small Molecules to Inhibit Furin for Dengue - Drug Profile
Small Molecules to Inhibit NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile
Small Molecules to Inhibit NS4b for Dengue - Drug Profile
Small Molecules to Inhibit Protease for Dengue - Drug Profile
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Dengue Virus Infections - Drug Profile
Small Molecules to Inhibit Serine Protease for Viral Infections - Drug Profile
ST-148 - Drug Profile
ST-324 - Drug Profile
ST-610 - Drug Profile
Synthetic Peptides for West Nile Virus and Dengue Virus Infections - Drug Profile
TAK-003 - Drug Profile
TVX-005 - Drug Profile
UV-4B - Drug Profile
V-180 - Drug Profile
Viral PMO-X - Drug Profile
VIS-513 - Drug Profile
Dengue - Recent Pipeline Updates
Dengue - Dormant Projects
Dengue - Discontinued Products
Dengue - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Dengue, H1 2015
Number of Products under Development for Dengue - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Dengue - Pipeline by Agilvax, Inc., H1 2015
Dengue - Pipeline by AltraVax Inc., H1 2015
Dengue - Pipeline by Arbovax, Inc., H1 2015
Dengue - Pipeline by BioDiem Ltd, H1 2015
Dengue - Pipeline by Biotron Limited, H1 2015
Dengue - Pipeline by Cocrystal Pharma, Inc., H1 2015
Dengue - Pipeline by Codagenix, Inc., H1 2015
Dengue - Pipeline by FIT Biotech Oyj, H1 2015
Dengue - Pipeline by GlaxoSmithKline plc, H1 2015
Dengue - Pipeline by Humabs BioMed SA, H1 2015
Dengue - Pipeline by Immunovaccine, Inc., H1 2015
Dengue - Pipeline by Johnson & Johnson, H1 2015
Dengue - Pipeline by Kineta, Inc., H1 2015
Dengue - Pipeline by MacroGenics, Inc., H1 2015
Dengue - Pipeline by Medivir AB, H1 2015
Dengue - Pipeline by Merck & Co., Inc., H1 2015
Dengue - Pipeline by Molplex Ltd., H1 2015
Dengue - Pipeline by Myelo Therapeutics GmbH, H1 2015
Dengue - Pipeline by NanoViricides, Inc., H1 2015
Dengue - Pipeline by Panacea Biotec Limited, H1 2015
Dengue - Pipeline by PaxVax, H1 2015
Dengue - Pipeline by Prosetta Antiviral Inc., H1 2015
Dengue - Pipeline by RFS Pharma, LLC, H1 2015
Dengue - Pipeline by Sanofi Pasteur SA, H1 2015
Dengue - Pipeline by Sarepta Therapeutics, Inc., H1 2015
Dengue - Pipeline by SIGA Technologies, Inc., H1 2015
Dengue - Pipeline by SKAU Vaccines ApS, H1 2015
Dengue - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
Dengue - Pipeline by TechnoVax, Inc., H1 2015
Dengue - Pipeline by Themis Bioscience GmbH, H1 2015
Dengue - Pipeline by United Therapeutics Corporation, H1 2015
Dengue - Pipeline by VaxInnate Corporation, H1 2015
Dengue - Pipeline by Visterra, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Dengue Therapeutics - Recent Pipeline Updates, H1 2015
Dengue - Dormant Projects, H1 2015
Dengue - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Dengue, H1 2015
Number of Products under Development for Dengue - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Agilvax, Inc.
AltraVax Inc.
Arbovax, Inc.
BioDiem Ltd
Biotron Limited
Cocrystal Pharma, Inc.
Codagenix, Inc.
FIT Biotech Oyj
GlaxoSmithKline plc
Humabs BioMed SA
Immunovaccine, Inc.
Johnson & Johnson
Kineta, Inc.
MacroGenics, Inc.
Medivir AB
Merck & Co., Inc.
Molplex Ltd.
Myelo Therapeutics GmbH
NanoViricides, Inc.
Panacea Biotec Limited
PaxVax
Prosetta Antiviral Inc.
RFS Pharma, LLC
Sanofi Pasteur SA
Sarepta Therapeutics, Inc.
SIGA Technologies, Inc.
SKAU Vaccines ApS
Takeda Pharmaceutical Company Limited
TechnoVax, Inc.
Themis Bioscience GmbH
United Therapeutics Corporation
VaxInnate Corporation
Visterra, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.